Heparin Market Analysis

Route of Administration Segment Analysis

Based on the route of administration, the subcutaneous subtype is expected to lead with the largest revenue share of 65.5% in the heparin market. The dominance is effectively attributable to the increasing adoption of low molecular weight heparin and its cost-effectiveness. According to the article published by NIH in March 2025, the low-molecular-weight heparins such as enoxaparin and dalteparin are mostly administered through subcutaneous injection for the prophylaxis and treatment of venous thromboembolism in hospitalized, surgical, and high-risk patients, as per FDA-approved indications and clinical guidelines. In addition, it also notes that this route is highly preferred owing to the predictable anticoagulant effects, longer half-life, and reduced need for monitoring when compared to unfractionated heparin. Furthermore, LMWHs are also recommended for special populations such as pregnant women, pediatric patients, and older adults, thereby highlighting widespread adoption of subcutaneous administration.

Type Segment Analysis

By the conclusion of 2035, the low-molecular-weight heparin segment is expected to grow with a considerable share in the heparin market. It is mostly preferred anticoagulant globally owing to more predictable pharmacokinetics, longer half-life, lower risk of heparin-induced thrombocytopenia, and reduced monitoring needs when compared with unfractionated heparin. The increasing prevalence of cardiovascular diseases and the rising number of surgical procedures worldwide are also fueling LMWH adoption. The availability of prefilled syringes and patient-friendly subcutaneous administration supports its extensive utilization in both hospital and home settings. Ongoing research and development into novel LMWH formulations and biosimilars are expected to expand market accessibility in the upcoming years. Moreover, clinical guidelines from leading health authorities continue to recommend LMWH for thromboprophylaxis in high-risk populations, reinforcing its position in the heparin market.

Source Segment Analysis

The porcine-derived heparin is anticipated to grow with a considerable share in the heparin market over the forecasted years. The growth of the segment is since porcine mucosa being the most established and widely accepted raw material for heparin APIs with consistent quality and clinical history. In May 2023, Bioiberica and Vall Companys together announced the launch of Biovall Heparin Science, which is a joint project to produce crude heparin from porcine intestinal mucosa, promoting a sustainable circular economy by reusing porcine co-products. This initiative is approved by local authorities, involves 25,000 tonnes of mucosa annually, meeting Spain’s total heparin demand under strict GMP standards. Bioiberica, the world’s leading heparin API producer that strongly emphasizes traceability, quality, and safety, reinforces porcine-derived heparin’s central role in global anticoagulant supply.

Our in-depth analysis of the global heparin market includes the following segments: